title: Normal prostate tissue free of any pathological alteration from organ donor PD004 PD006U95Av2

source_name: PD004, normal prostate tissue free of any pathological alteration from organ donor PD004


title: Normal prostate tissue free of any pathological alteration from organ donor PD001 PD001U95Av2

status: Public on Jan 16 2007

type: RNA

city: Houston

first: Federico

middle: Alberto

last: Monzon

state: TX

address: 6565 Fannin St, MS205

department: Pathology

country: USA

institute: The Methodist Hospital

description: Gene expression data from normal prostate tissues free of any pathological alteration

hyb_protocol: Following fragmentation, 15 ug of cRNA were hybridized for 16 hr at 45C on GeneChip HG-U95Av2 array. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.

scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.

data_processing: The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 200.

label: biotin

molecule: total RNA

organism: Homo sapiens

source_name: PD001, normal prostate tissue free of any pathological alteration from organ donor PD001

label_protocol: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 5 ug total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).

extract_protocol: Total RNA was extracted with Qiagen Rneasy kit according to the manufacturer's instructions.

treatment_protocol: Donor prostate tissues were obtained at the time of organ donation in brain-dead men. Samples were collected from peripheral zone of the prostate gland with at least 60% glandular components and free of any pathological alteration.

tag: Tissue:normal prostate tissue free of any pathological alteration from brain-dead organ donor

tag: Age

tag: Race

value: Caucasian


title: Normal prostate tissue free of any pathological alteration from organ donor PD005 PD004U95Av2

source_name: PD005, normal prostate tissue free of any pathological alteration from organ donor PD005


title: Normal prostate tissue free of any pathological alteration from organ donor PD008 PD008U95Av2

source_name: PD008, normal prostate tissue free of any pathological alteration from organ donor PD008

value: African American


title: Tumor samples from patient No.63 PT63U95Av2

description: Gene expression data from primary prostate cancer

source_name: PT63, tumor samples from patient No.63

treatment_protocol: Fresh prostate tissues were recovered immediately after surgical removal. Tissues were dissected/trimmed to obtain pure tumor then snap frozen in liquid nitrogen within 30 mintues of excision and stored in -80C untill RNA extraction. An H&E stained frozen section of each sample was evaluated by a pathologist, to determine epithelial and stromal content and verify the presence of tumor in the sample. Only tumor tissues with less than 30% of tromal components were selected.

tag: Tissue

value: primary prostate tumor

tag: Tumor stage

tag: Gleason Grade


title: Squamous cell carcinoma 3231

status: Public on Nov 10 2006

city: st louis

first: Yan

last: Lu

state: MO

address: 660 s. euclid ave

institute: washington univ.

description: Squamous cell carcinoma

hyb_protocol: standard Affymetrix procedures

scan_protocol: standard Affymetrix procedures

data_processing: Robust Multichip Average

source_name: Squamous cell carcinoma

label_protocol: Approximately 1 to 5 µg of total RNA was processed to produce biotinylated cRNA targets.

extract_protocol: standard Affymetrix procedures

tag: Gender

value: M; age:62; cancer type:Squamous cell carcinoma


title: Adenocarcinoma 3227

description: Adenocarcinoma

source_name: Adenocarcinoma

value: F; age:55; cancer type:Adenocarcinoma


title: Squamous cell carcinoma 3228

description: Squamous cell carcinoma

value: M; age:52; cancer type:Squamous cell carcinoma


title: Adenocarcinoma 3230

description: Adenocarcinoma

value: M; age:75; cancer type:Adenocarcinoma


title: Squamous cell carcinoma

description: Squamous cell carcinoma

value: F; age:79; cancer type:Squamous cell carcinoma


title: Normal prostate tissue free of any pathological alteration from organ donor PD003 PD003U95Av2

source_name: PD003, normal prostate tissue free of any pathological alteration from organ donor PD003


title: Adenocarcinoma 3223

description: Adenocarcinoma

value: F; age:48; cancer type:Adenocarcinoma


title: Normal prostate tissue free of any pathological alteration from organ donor PD002 PD002U95Av2

source_name: PD002, normal prostate tissue free of any pathological alteration from organ donor PD002


title: Squamous cell carcinoma 3224

description: Squamous cell carcinoma

value: M; age:75; cancer type:Squamous cell carcinoma


title: Adenocarcinoma 3226

description: Adenocarcinoma


title: Adenocarcinoma 3329

description: Adenocarcinoma

value: F; age:60; cancer type:Adenocarcinoma


title: Squamous cell carcinoma 3221

description: Squamous cell carcinoma

value: M; age:63; cancer type:Squamous cell carcinoma


title: Squamous cell carcinoma 3220

description: Squamous cell carcinoma

value: F; age:72; cancer type:Squamous cell carcinoma


title: large cell undiff 3222

description: large cell undiff

source_name: large cell undiff

value: M; age:66; cancer type:large cell undiff


title: Adenocarcinoma 3218

description: Adenocarcinoma

value: F; age:74; cancer type:Adenocarcinoma


title: large cell undiff 3219

description: large cell undiff

value: F; age:64; cancer type:large cell undiff


title: Squamous cell carcinoma 3217

description: Squamous cell carcinoma

value: M; age:51; cancer type:Squamous cell carcinoma


title: Squamous cell carcinoma 3215

description: Squamous cell carcinoma

value: F; age:64; cancer type:Squamous cell carcinoma


title: Squamous cell carcinoma 3214

description: Squamous cell carcinoma


title: Squamous cell carcinoma 3209

description: Squamous cell carcinoma

value: M; age:81; cancer type:Squamous cell carcinoma


title: Adenocarcinoma 3213

description: Adenocarcinoma

value: F; age:81; cancer type:Adenocarcinoma


title: Squamous cell carcinoma 3216

description: Squamous cell carcinoma

value: F; age:65; cancer type:Squamous cell carcinoma


title: Adenocarcinoma 3211

description: Adenocarcinoma

value: F; age:63; cancer type:Adenocarcinoma


title: Adenocarcinoma 3210

description: Adenocarcinoma

value: F; age:67; cancer type:Adenocarcinoma


title: large cell neuroendocrine 3212

description: large cell neuroendocrine

source_name: large cell neuroendocrine

value: M; age:65; cancer type:large cell neuroendocrine


title: Squamous cell carcinoma 3208

description: Squamous cell carcinoma

value: M; age:77; cancer type:Squamous cell carcinoma


title: Adenocarcinoma 3205

description: Adenocarcinoma

value: M; age:66; cancer type:Adenocarcinoma


title: Squamous cell carcinoma 3206

description: Squamous cell carcinoma

value: U; age:63; cancer type:Squamous cell carcinoma


title: undifferentiated 3207

description: undifferentiated

source_name: undifferentiated

value: M; age:71; cancer type:undifferentiated


title: Squamous cell carcinoma 3201

description: Squamous cell carcinoma

value: F; age:61; cancer type:Squamous cell carcinoma


title: Squamous cell carcinoma 3204

description: Squamous cell carcinoma

value: M; age:70; cancer type:Squamous cell carcinoma


title: Adenocarcinoma 3200

description: Adenocarcinoma

value: M; age:61; cancer type:Adenocarcinoma


title: Squamous cell carcinoma 3203

description: Squamous cell carcinoma

value: M; age:63; cancer type:Squamous cell carcinoma


title: Adenocarcinoma 3196

description: Adenocarcinoma

value: M; Age:71; Adenocarcinoma


title: Squamous cell carcinoma 3199

description: Squamous cell carcinoma


title: Adenocarcinoma 3202

description: Adenocarcinoma

value: M; age:65; cancer type:Adenocarcinoma


title: Adenocarcinoma 3197

description: Adenocarcinoma

value: M; age:70; cancer type:Adenocarcinoma


title: WT899A

status: Public on Oct 28 2006

city: New York

first: Chi-Ming

last: Li

state: NY

address: 1130 St Nicholas Ave, rm607

department: ICG

institute: Columbia University

description: Sporadic Wilms tumor

hyb_protocol: affymetrix standard protocol

scan_protocol: affymetrix scanner

source_name: Class I Wilms tumor

label_protocol: one cycle labelling

extract_protocol: Trizol extraction

tag: Class I Wilms tumor


title: WT616B

description: Sporadic Wilms tumor


title: WT3665

description: Sporadic Wilms tumor


title: BCell_activated_sample3

city: Boston

first: Marc

middle: E.

last: Lenburg

state: MA

address: 715 Albany Street, E613B

department: Genetics and Genomics

institute: Boston University School of Medicine

description: flow-cytometry: B220+, CD5–, CD19+, CD25+, CD69+, B7-1+, B7-2+, IgDlo, sIgMlo; clinical-signs: none

hyb_protocol: For each GeneChip, 20 micrograms of the labeled product was fragmented in 40 mM Tris-acetate, pH 8.1, 100mM KOAc, 30mM MgOAc, for 35 minutes at 94 degrees-Celsius, to an average size of 35 to 200 bases.  15 micrograms of this fragmented, biotinylated cRNA, along with hybridization controls supplied by the manufacturer (Affymetrix), were hybridized to the arrays for 16 hours at 45 degrees-Celsius and 60 rpm.  Arrays were washed and stained according to the standard Antibody Amplification for Eukaryotic Targets protocol (Affymetrix).

scan_protocol: The stained GeneChip arrays were scanned at 488 nm using an Affymetrix Gene Chip Scanner 3000 (Affymetrix, Santa Clara, CA).

data_processing: MAS5.0, target intensity = 500

organism: Mus musculus

source_name: wildtype activated B-Cells

label_protocol: Using a poly-dT primer incorporating a T7 promoter, double-stranded cDNA was synthesized from 10 micrograms total RNA using a cDNA synthesis kit (SuperScript double-stranded cDNA synthesis kit; Invitrogen, Carlsbad, CA).  Double-stranded cDNA was purified by phenol/chloroform extraction using a Phase-Lock Gel (PLG Heavy Brinkmann Instruments, Westbury, NY) followed by ethanol precipitation.  Biotin-labeled cRNA was generated from the double-stranded cDNA template though in-vitro transcription with T7 polymerase, and a nucleotide mix containing biotinylated CTP and UTP (Enzo RNA Transcript Labeling Kit; Enzo Diagnostics, Farmingdale, NY).  The biotinylated cRNA was purified using RNeasy affinity columns (Qiagen, Valencia, MD).

extract_protocol: Total RNA was isolated with the guanidinium thiocyanate method, extracted with acid phenol and precipitated from 2-propanol.

tag: genotype

value: wildtype

tag: cell-type

value: activated

tag: splenomegaly

tag: Ig clonality

value: polyclonal


title: WT3663

description: Sporadic Wilms tumor


title: WT564-2

description: Sporadic Wilms tumor with WT1 mutation

source_name: Class II Wilms tumor

tag: Class II Wilms tumor


title: Squamous cell carcinoma 3198

description: Squamous cell carcinoma

value: M; age:66; cancer type:Squamous cell carcinoma


title: WT3560

description: Sporadic Wilms tumor


title: BCell_resting_sample5

description: flow-cytometry: B220+, CD5–, CD19+, CD25–, CD69–, B7-1–, B7-2–, IgD+, sIgM+; clinical-signs: none

source_name: wildtype resting B-Cells

value: resting


title: BCell_activated_sample2


title: BCell_lymphoma_aggressive_sample6

description: flow-cytometry: B220+, CD5+, CD9+, CD19+, CD23lo, CD25–, CD69–, sIgM+, B7-1+, B7-2+; clinical-signs: end-stage

source_name: aggressive E-mu-BRD2 mediated lymphoma

value: severe

value: monoclonal


title: WT3531

description: Sporadic Wilms tumor


title: BCell_lymphoma_aggressive_sample7


title: WT2621

description: Sporadic Wilms tumor


title: WT2933

description: Sporadic Wilms tumor


title: WT2122

description: Sporadic Wilms tumor


title: WT2596

description: Sporadic Wilms tumor


title: WT2071A

description: Sporadic Wilms tumor


title: BCell_lymphoma_aggressive_sample5


title: BCell_lymphoma_aggressive_sample4


title: BCell_lymphoma_aggressive_sample3


title: WT2110

description: Sporadic Wilms tumor


title: WAGR3499

description: Wilms tumor from WAGR patient


title: WAGR3500

description: Wilms tumor from WAGR patient


title: BCell_lymphoma_transitional_sample4

description: flow-cytometry: ND; clinical-signs: failure to nest

source_name: transitional E-mu-BRD2 mediated lymphoma

value: moderately severe

value: oligoclonal


title: WAGR3498

description: Wilms tumor from WAGR patient


title: BCell_lymphoma_transitional_sample3

value: mild


title: BCell_lymphoma_transitional_sample5


title: WAGR3497

description: Wilms tumor from WAGR patient


title: BCell_resting_sample4

description: flow-cytometry: B220+, CD5–, CD19+, CD25–, CD69–, B7-1–, B7-2–, IgD+, sIgM+; clinical-signs: conjunctivitis

source_name: E-mu-BRD2 resting B-Cells


title: BCell_lymphoma_transitional_sample2


title: WAGR3494

description: Wilms tumor from WAGR patient


title: BCell_lymphoma_marginal_sample6

description: flow-cytometry: B220+, CD5+, CD11b+; clinical-signs: paralysis

source_name: marginal E-mu-BRD2 mediated lymphoma

value: moderate


title: WAGR3495

description: Wilms tumor from WAGR patient


title: WAGR3496

description: Wilms tumor from WAGR patient


title: BCell_lymphoma_marginal_sample4

description: flow-cytometry: ND; clinical-signs: leg tumor


title: BCell_lymphoma_aggressive_sample2


title: BCell_lymphoma_transitional_sample1


title: WAGR3308

description: Wilms tumor from WAGR patient


title: WAGR3306

description: Wilms tumor from WAGR patient


title: WAGR3309

description: Wilms tumor from WAGR patient


title: BCell_lymphoma_marginal_sample3


title: BCell_lymphoma_aggressive_sample1


title: BCell_lymphoma_marginal_sample5

description: flow-cytometry: ND; clinical-signs: haunch tumor


title: FKi3287

description: fetal kidney

source_name: fetal kidney

tag: fetal kidney


title: BCell_resting_sample3


title: BCell_lymphoma_marginal_sample1

description: flow-cytometry: ND; clinical-signs: neck tumor

value: marginal


title: FKi2958

description: fetal kidney


title: BCell_lymphoma_marginal_sample2


title: FKi3284

description: fetal kidney


title: DRASH3501

description: Wilms tumor from DDS patient


title: DRASH3502

description: Wilms tumor from DDS patient


title: DRASH3311

description: Wilms tumor from DDS patient


title: BCell_resting_sample2


title: blood_probandS_female_rep3

status: Public on Aug 12 2006

city: Muenster

first: Martin

last: Eisenacher

state: NRW

address: von-Esmarch-Str. 56

department: Integrierte Funktionelle Genomik (IFG)

country: Germany

description: HG_U95Av2, original experiment name: S33-130-300801_TGT1000

data_processing: Affymetrix Microarray Suite version 5.0, statistical algorithm, scaling target value 1000

source_name: venous blood of adult human proband

label_protocol: during in-vitro transcription; standard Affymetrix procedures

extract_protocol: lysis in RLT buffer (Qiagen); total-RNA extracted with RNeasy kit (Qiagen)

tag: total RNA of approx. 50 ml human venous blood, probands have no known diseases


title: Female BALB/c Lacrimal Placebo, biological rep 3 (Affymetrix)

status: Public on Sep 12 2006

first: Nathaniel

last: Treister

address: 20 Staniford Street

institute: Schepens Eye Research Institute

description: Lacrimal gland gene expression from ovarectomized mice treated with placebo for 14 days.

hyb_protocol: Following fragmentation, 20 microg of cRNA were hybridized for 18 hr at 45C on a Affymetrix GeneChip Mouse Expression Array 430A using a Affymetrix hybridization oven. GeneChips were washed and stained with streptavidin-Alexa 647 and washed again using a Model 450 Fluidics station and Affymetrix GeneChip Operating Software (GCOS) .

scan_protocol: GeneChips were scanned with a Affymetrix Model 7000 scanner running GCOS v1.3 software.

data_processing: Data were analyzed with GCOS software using the default settings.  No normalization was performed.

source_name: Lacrimal glands from placebo treated female BALB/c mice ( glands pooled from 5-6 mice).

label_protocol: Biotinylated cRNA were prepared according to the standard Codelink protocol from 2 microg total RNA using a CodeLink Expression Assay Reagent Kit.

extract_protocol: RNA was purified with Trizol and RNAqueous spin columns following the manufacturer's instructions.


title: Female BALB/c Lacrimal Testosterone, biological rep 1 (Affymetrix)

description: Lacrimal gland gene expression from ovarectomized mice treated with testosterone for 14 days.

source_name: Lacrimal glands from testosterone treated female BALB/c mice ( glands pooled from 5-6 mice).


title: blood_probandH_male_rep3

description: HG_U95Av2, original experiment name: S32-128-250701_TGT1000


title: blood_probandP_male_rep1

description: HG_U95Av2, original experiment name: S-41.154-131101_TGT1000


title: Female BALB/c Lacrimal Testosterone, biological rep 2 (Affymetrix)


title: blood_probandEB_male_rep3

description: HG_U95Av2, original experiment name: S31-127-250701_TGT1000


title: blood_probandK_female_rep1

description: HG_U95Av2, original experiment name: S-41.156-131101_TGT1000


title: DRASH3310

description: Wilms tumor from DDS patient


title: Female BALB/c Lacrimal Placebo, biological rep 2 (Affymetrix)


title: BCell_activated_sample1


title: blood_probandG_male_rep1

description: HG_U95Av2, original experiment name: S-41.155-131101_TGT1000


title: Female BALB/c Lacrimal Placebo, biological rep 1 (Affymetrix)


title: BCell_resting_sample1


title: blood_probandS_female_rep2

description: HG_U95Av2, original experiment name: S32-129-250701_TGT1000


title: blood_probandH_male_rep2

description: HG_U95Av2, original experiment name: S31-125-250701_TGT1000


title: Female BALB/c Lacrimal Testosterone, biological rep 3 (Affymetrix)


title: blood_probandA_female_rep1

description: HG_U95Av2, original experiment name: S-41.157-131101_TGT1000


title: Mouse_E12_Endoderm_3

status: Public on Jul 15 2006

city: Copenhagen

first: Jorgen

last: Olsen

address: Blegdamsvej 3

department: Department of Cellular and Molecular Medicine

country: Denmark

institute: University of Copenhagen

description: Endoderm form E12 mouse embryos were dissected out from collagenase digested fetal intestine. Material from 10-12 fetuses were pooled.

data_processing: RMA processing using quantile normalization

label: Phycoerythrin

source_name: Endoderm

extract_protocol: Qiagen RNeasy total RNA extraction system with on column DNAse I digestion

tag: Strain:C57BL/6, Tissue:E12 mesenchyme


title: Mouse_E12_Endoderm_4


status: Public on Jun 29 2006

city: Aachen

last: Zenke

address: Universitatsklinikum Aachen, RWTH

department: Cell Biology

institute: Institute for Biomedical Engineering

description: Hematopoietic stem/progenitor cells left untreated and subjected to expression analysis on HG_U95Av2 DNA microarray.

hyb_protocol: Affymetrix arrays were prehybridized with 200 ml MES hybridization buffer for 10 minutes at 45°C with rotation (60 U/min) in an Affymetrix hybridization oven 640. After removing the prehybridization solution, 10 µg of labeled cRNA in 200 ml MES hybridization buffer were applied to the array thereby leaving a small air bubble. Arrays were incubated overnight at 45°C with rotation (60 U/min) in the hybridization chamber.

data_processing: CEL files were processed with R (www.r-project.org) and Bioconductor (www.bioconductor.org). Scanned array were subjected to multiple quality control tests. This include scaling factor control, control for aberration of average background value, present call percentage on each chip, RNA degradation, images artifact detection.

label: biotinylated UTP and CTP

source_name: CD34+ hematopoietic stem/progenitor cells were isolated from human cord blood.

label_protocol:
In vitro transcription employing double stranded cDNA as template and biotinylated UTP and CTP (Perkin Elmer/ENZO) as label was performed with the MEGAscript kit from Ambion according to the manufacturer's instructions.
Labeled RNA was fragmented by heating to 95°C for 35 minutes in 200 mM TRIS (pH 8.1), 500 mM KOAc, 150 mM MgOAc buffer.

growth_protocol: CD34+ hematopoietic stem/progenitor cells (HPC) were isolated using the MACS system (Miltenyi Biotec, Bergisch-Gladbach, Germany).  Purity was 83-90%. CD34+ cells (0.3-0.5x106 cells/ml) were cultured in StemSpan serum free medium (StemCell Technologies Inc., Vancouver, Canada) with 100 ng/ml SCF, 50 ng/ml Flt3 ligand (FL), 20 ng/ml thrombopoietin (Tpo) and 10 ng/ml hyper-IL-6 (Ju et al., Eur. J. Cell Biol. 82, 75-86, 2003; Hacker et al., Nat. Immunol. 4, 380-386, 2003.). Growth factors were added every 2 days and cells were maintained at 1x106 cells/ml cell density. Cells were amplified in vitro for 10-14 days.

extract_protocol: Total RNA was extracted using RNeasy Midi kit (Qiagen, Hilden, Germany) using the manufacturer’s buffers and protocols. An additional DNAse digestion with RNAse free DNAse (Qiagen) was performed. First and second strand cDNA synthesis were done with 7 mg total RNA with the SuperScript Choice system (Gibco BRL) and a T7-(dT)24 Primer (Biotez, Berlin, Germany).

treatment_protocol: Hematopoietic stem/progenitor cells untreated (control)

tag: CD34+ hematopoietic stem/progenitor cells (HPC) were isolated from human cord blood and amplified in vitro for 10-14 days in serum-free medium with specific cytokines (Ju et al., Eur. J. Cell Biol. 82, 75-86, 2003; Hacker et al., Nat. Immunol. 4, 380-386, 2003). HPC were left untreated (control).


title: Mouse_E12_mesenchyme_3

description: Mesenchyme form E12 mouse embryos were dissected out from collagenase digested fetal intestine. Material from 10-12 fetuses were pooled.

source_name: mesenchyme


title: Mouse_E12_mesenchyme_2


title: Hematopoietic stem/progenitor cells treated with TGF-beta1 for 2 hours

hyb_protocol: Affymetrix arrays were prehybridized with 200 ml MES hybridization buffer for 10 minutes at 45 C with rotation (60 U/min) in an Affymetrix hybridization oven 640. After removing the prehybridization solution, 10 microgramm of labeled cRNA in 200 ml MES hybridization buffer were applied to the array thereby leaving a small air bubble. Arrays were incubated overnight at 45 C with rotation (60 U/min) in the hybridization chamber.

source_name: CD34+ hematopoietic stem/progenitor cells were isolated from human cord blood

label_protocol:
In vitro transcription employing double stranded cDNA as template and biotinylated UTP and CTP (Perkin Elmer/ENZO) as label was performed with the MEGAscript kit from Ambion according to the manufacturer's instructions.
Labeled RNA was fragmented by heating to 95 C for 35 minutes in 200 mM TRIS (pH 8.1), 500 mM KOAc, 150 mM MgOAc buffer.

growth_protocol: CD34+ hematopoietic stem/progenitor cells (HPC) were isolated using the MACS system (Miltenyi Biotec, Bergisch-Gladbach, Germany).  Purity was 83-90%. CD34+ cells (0.3-0.5x106 cells/ml) were cultured in StemSpan serum free medium (StemCell Technologies Inc., Vancouver, Canada) with 100 ng/ml SCF, 50 ng/ml Flt3 ligand (FL), 20 ng/ml thrombopoietin (Tpo) and 10 ng/ml hyper-IL-6 (Ju et al., Eur. J. Cell Biol. 82, 75-86, 2003; Hacker et al., Nat. Immunol. 4, 380-386, 2003.). Growth factors were added every 2 days and cells were maintained at 1x10E6 cells/ml cell density. Cells were amplified in vitro for 10-14 days.

extract_protocol: Total RNA was extracted using RNeasy Midi kit (Qiagen, Hilden, Germany) using the manufacturer buffers and protocols. An additional DNAse digestion with RNAse free DNAse (Qiagen) was performed. First and second strand cDNA synthesis were done with 7 mg total RNA with the SuperScript Choice system (Gibco BRL) and a T7-(dT)24 Primer (Biotez, Berlin, Germany).

treatment_protocol: Hematopoietic stem/progenitor cells treated for 2 hours with TGF-beta1.

tag: CD34+ hematopoietic stem/progenitor cells (HPC) were isolated from human cord blood and amplified in vitro for 10-14 days in serum-free medium with specific cytokines (Ju et al., Eur. J. Cell Biol. 82, 75-86, 2003; Hacker et al., Nat. Immunol. 4, 380-386, 2003). HPC were treated with TGF-beta1 for 2 hours


title: E31

status: Public on Jun 01 2006

city: Atlanta

last: Wang

state: GA

institute: Centers for Diseases Control

description: This sample is from Rotavirus acute phase infection of patient #9 (see Table 1 in paper)

source_name: Peripheral Blood Mononuclear Cell (PBMC)


title: Dendritic cells derived from CD34+ hematopoietic stem/progenitor cells; treated for 36 hours with TGF-beta1

description: Dendritic cell derived from CD34+ hematopoietic stem/progenitor untreated (control)

hyb_protocol: Affymetrix arrays were prehybridized with 200 microl MES hybridization buffer for 10 minutes at 45 C with rotation (60 U/min) in an Affymetrix hybridization oven 640. After removing the prehybridization solution, 10 microg of labeled cRNA in 200 microl MES hybridization buffer were applied to the array thereby leaving a small air bubble. Arrays were incubated overnight at 45 C with rotation (60 U/min) in the hybridization chamber.

data_processing: CEL files were processed with R(www.r-project.org) and Bioconductor (www.bioconductor.org). Scanned array were subjected to multiple quality control tests. This include scaling factor control, control for aberration of average background value, present call percentage on each chip, RNA degradation, images artifact detection.

source_name: CD34+ hematopoietic stem/progenitor derived dendritic cells.

growth_protocol: CD34+ hematopoietic stem/progenitor cells were isolated using the MACS system (Miltenyi Biotec, Bergisch-Gladbach, Germany).  Purity was 83-90%. CD34+ cells (0.3-0.5x10E6 cells/ml) were cultured in StemSpan serum free medium (StemCell Technologies Inc., Vancouver, Canada) with 100 ng/ml SCF, 50 ng/ml Flt3 ligand (FL), 20 ng/ml thrombopoietin (Tpo) and 10 ng/ml hyper-IL-6 (Ju et al., Eur. J. Cell Biol. 82, 75-86, 2003; Hacker et al., Nat. Immunol. 4, 380-386, 2003.). Growth factors were added every 2 days and cells were maintained at 1x10E6 cells/ml cell density. Cells were amplified in vitro for 10-14 days. After 10-14 days of culture progenitor cells were induced to differentiate into DC in RPMI medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 0.1 microM Beta-mercaptoethanol, 100 U/ml penicillin and streptomycin (GIBCO-BRL) and 500 U/ml GM-CSF, 500 U/ml IL-4 for 6 days with or without 10 ng/ml TGF-beta1 as indicated (0.5x10E6 cells/ml).  Every 2 days growth factors were added and cells were maintained at 0.5x10E6 cells/ml cell density.

extract_protocol: Total RNA was extracted using RNeasy Midi kit (Qiagen, Hilden, Germany) using the manufacturer�s buffers and protocols. An additional DNAse digestion with RNAse free DNAse (Qiagen) was performed. First and second strand cDNA synthesis were done with 7 microg total RNA with the SuperScript Choice system (Gibco BRL) and a T7-(dT)24 Primer (Biotez, Berlin, Germany).

treatment_protocol:
CD34+ hematopoietic stem/progenitor cells were isolated from human cord blood and amplified in vitro for 10-14 days in serum-free medium with specific cytokines (Ju et al., Eur. J. Cell Biol. 82, 75-86, 2003; Hacker et al., Nat. Immunol. 4, 380-386, 2003). Cultured progenitor cells were induced to differentiate into DC in RPMI medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 0.1 microM Beta-mercaptoethanol, 100 U/ml penicillin and streptomycin (GIBCO-BRL) and 500 U/ml GM-CSF, 500 U/ml IL-4 for 6 days with or without 10 ng/ml TGF-beta1 as indicated (0.5x10E6 cells/ml). Every 2 days growth factors were added and cells were maintained at 0.5x10E6 cells/ml cell density.
DC were left untreated as control.

tag: DC were treated with TGF-beta1 for 36 hours.


title: Dendritic cells derived from CD34+ hematopoietic stem/progenitor cells; untreated (control)

extract_protocol: Total RNA was extracted using RNeasy Midi kit (Qiagen, Hilden, Germany) using the manufacturer’s buffers and protocols. An additional DNAse digestion with RNAse free DNAse (Qiagen) was performed. First and second strand cDNA synthesis were done with 7 microg total RNA with the SuperScript Choice system (Gibco BRL) and a T7-(dT)24 Primer (Biotez, Berlin, Germany).

tag: CD34+ hematopoietic stem/progenitor cells were isolated from human cord blood and amplified in vitro for 10-14 days in serum-free medium with specific cytokines (Ju et al., Eur. J. Cell Biol. 82, 75-86, 2003; Hacker et al., Nat. Immunol. 4, 380-386, 2003). Cultured progenitor cells were induced to differentiate into DC in RPMI medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 0.1 microM Beta-mercaptoethanol, 100 U/ml penicillin and streptomycin (GIBCO-BRL) and 500 U/ml GM-CSF, 500 U/ml IL-4 for 6 days with or without 10 ng/ml TGF-beta1 as indicated (0.5x10E6 cells/ml). Every 2 days growth factors were added and cells were maintained at 0.5x10E6 cells/ml cell density.

tag: DC were left untreated as control.


title: RI39

description: This sample is from Rotavirus acute phase infection of patient #7(see Table 1 in paper)


title: Conv_E31

description: This sample is from Rotavirus infection convalescence phase of patient E31


title: Conv_E35

description: This sample is from Rotavirus infection convalescence phase of patient E35


title: RI57

description: This sample is from Rotavirus acute phase infection of patient #8(see Table 1 in paper)


title: Conv_RI45

description: This sample is from Rotavirus infection convalescence phase of patient RI34


title: Dendritic cells derived from CD34+ hematopoietic stem/progenitor cells; treated for 16 hours with TGF-beta1

tag: DC were treated with TGF-beta1 for 16 hours


title: Mouse_E12_Endoderm_2

tag: Strain:C57BL/6, Tissue:E12 endoderm


title: Conv_RI34

description: This sample is from Rotavirus infection convalescence phase of patient RI39


title: E35

description: This sample is from Rotavirus acute phase infection of patient #10 (see Table 1 in paper)


title: Dendritic cells derived from CD34+ hematopoietic stem/progenitor cells; treated for 4 hours with TGF-beta1

tag: DC were treated with TGF-beta1 during 4 hours


title: Hematopoietic stem/progenitor cells treated with TGF-beta1 for 16 hours

treatment_protocol: Hematopoietic stem/progenitor cells treated for 16 hours with TGF-beta1.

tag: CD34+ hematopoietic stem/progenitor cells (HPC) were isolated from human cord blood and amplified in vitro for 10-14 days in serum-free medium with specific cytokines (Ju et al., Eur. J. Cell Biol. 82, 75-86, 2003; Hacker et al., Nat. Immunol. 4, 380-386, 2003). HPC were treated with TGF-beta1 for 16 hours.


title: RI59

description: This sample is from Rotavirus acute phase infection of patient #6(see Table 1 in paper)


title: Conv_RI39


title: Mouse_E12_mesenchyme_4


title: RI34

description: This sample is from Rotavirus acute phase infection of patient #5(see Table 1 in paper)


title: RI36

description: This sample is from Rotavirus acute phase infection of patient #2(see Table 1 in paper)


title: E40C

description: This sample is from normal control #8(see Table 1 in paper)


title: E8C

description: This sampleis from normal control #5(see Table 1 in paper)


title: RI47

description: This sample is from Rotavirus acute phase infection of patient #3(see Table 1 in paper)


title: RI45

description: This sample is from Rotavirus acute phase infection of patient #4(see Table 1 in paper)


title: E4C

description: This sample is from normal control #3(see Table 1 in paper)


title: E9C

description: This sample is from normal control #6(see Table 1 in paper)


title: RI46

description: This sample is from Rotavirus acute phase infection of patient #1(see Table 1 in paper)


title: E10C

description: This sample is from normal control #7(see Table 1 in paper)


title: E2C

description: This sample is from normal control #1(see Table 1 in paper)


title: E5C

description: This sample is from normal control #4(see Table 1 in paper)


title: Hematopoietic stem/progenitor cells treated with TGF-beta1 for 4 hours

description: Hematopoietic stem/progenitor cells left untreated and subjected to expression analysis on HG_U95Av2 DNA microarray.

treatment_protocol: Hematopoietic stem/progenitor cells treated for 4 hours with TGF-beta1.

tag: CD34+ hematopoietic stem/progenitor cells (HPC) were isolated from human cord blood and amplified in vitro for 10-14 days in serum-free medium with specific cytokines (Ju et al., Eur. J. Cell Biol. 82, 75-86, 2003; Hacker et al., Nat. Immunol. 4, 380-386, 2003). HPC were treated with TGF-beta1 for 4 hours.


title: SP600125 experiment 48h TREATED

status: Public on May 16 2006

first: Miroslav

last: Blumenberg

address: 455 First Ave #874

department: Dermatology

institute: NYU School of Medicine

hyb_protocol: Standard Affymetrix protocol

scan_protocol: Standard Affymetrix protocol

data_processing: MAS5 GCOS

label: Standard Affymetrix protocol

source_name: Epidermal Keratinocytes

label_protocol: Standard Affymetrix protocol Standard Banno et al., J Biol Chem 279(31): 32633-32642.

treatment_protocol: 5 nM SP600125 (Calbiochem)

tag: ~70% confluent neonatal foreskin keratinocytes 3-4th passage, in KGM then starved in KBM for 24 hrs


title: E3C

description: This sample is from normal control #2(see Table 1 in paper)


title: SP600125 experiment 24h TREATED

extract_protocol: Standard Affymetrix protocol Standard Banno et al., J Biol Chem 279(31): 32633-32642.


title: SP600125 experiment 4h TREATED

growth_protocol: Standard Banno et al., J Biol Chem 279(31): 32633-32642.


title: SP600125 experiment 48h CONTROL


title: SP600125 experiment 24h CONTROL


title: SP600125 experiment 4h CONTROL


title: Expression data of rectal cancer T70

status: Public on Mar 29 2006

city: Bunkyo-ku

first: Toshiaki

last: Watanabe

state: Tokyo

department: Department of Surgical Oncology

country: Japan

institute: University of Tokyo

description: training-non-responder

data_processing: Affymetrix Microarray Suite version 5.0

source_name: Patient ID T70

label_protocol: Approximately 5 ug of total RNA was processed to produce biotinylated cRNA targets.

extract_protocol: Surgically isolated human colorectal cancer tissues were immediately frozen in liquid nitrogen. Tissues were lysed and total RNA was extracted using the Sepasol-RNA I (WAKO, Osaka, Japan) according to the manufacturer's instructions. Total RNA was then purified using an RNeasy column (Qiagen, Austin, TX).

tag: Tissue

value: rectal cancer


title: SP600125 experiment 1h TREATED


title: Expression data of rectal cancer TKR04T

description: training-responder

source_name: Patient ID TKR04T


title: Expression data of rectal cancer T46

description: training-non-responder

source_name: Patient ID T46


title: Expression data of rectal cancer T66

description: test-responder

source_name: Patient ID T66


title: Expression data of rectal cancer T36

description: training-non-responder

source_name: Patient ID T36


title: Expression data of rectal cancer TKR16T

description: training-non-responder

source_name: Patient ID TKR16T


title: Expression data of rectal cancer T67

description: test-non-responder

source_name: Patient ID T67


title: Expression data of rectal cancer T53

description: training-non-responder

source_name: Patient ID T53


title: Expression data of rectal cancer T57

description: training-non-responder

source_name: Patient ID T57


title: Expression data of rectal cancer T68

description: test-non-responder

source_name: Patient ID T68


title: Expression data of rectal cancer T71

description: training-non-responder

source_name: Patient ID T71


title: Expression data of rectal cancer T44

description: test-non-responder

source_name: Patient ID T44


title: Expression data of rectal cancer T82

description: test-non-responder

source_name: Patient ID T82


title: Expression data of rectal cancer T83

description: test-non-responder

source_name: Patient ID T83


title: Expression data of rectal cancer T52

description: training-non-responder

source_name: Patient ID T52


title: Expression data of rectal cancer T80

description: test-responder

source_name: Patient ID T80


title: Expression data of rectal cancer TKR15T

description: training-non-responder

source_name: Patient ID TKR15T


title: SP600125 experiment 1h CONTROL

source_name: Epidermal Keratinocytes


title: Expression data of rectal cancer T62

description: training-non-responder

source_name: Patient ID T62


title: Expression data of rectal cancer T43

description: training-non-responder

source_name: Patient ID T43


title: Expression data of rectal cancer TKR26T

description: training-non-responder

source_name: Patient ID TKR26T


title: Expression data of rectal cancer T51

description: training-non-responder

source_name: Patient ID T51


title: Expression data of rectal cancer TKR25T

description: training-non-responder

source_name: Patient ID TKR25T


title: Expression data of rectal cancer T48

description: training-non-responder

source_name: Patient ID T48


title: Expression data of rectal cancer T35

description: training-non-responder

source_name: Patient ID T35


title: Expression data of rectal cancer T55

description: training-non-responder

source_name: Patient ID T55


title: Expression data of rectal cancer T63

description: test-non-responder

source_name: Patient ID T63


title: Expression data of rectal cancer TKR13T

description: training-non-responder

source_name: Patient ID TKR13T


title: Expression data of rectal cancer T45

description: training-non-responder

source_name: Patient ID T45


title: Expression data of rectal cancer TKR18T

description: training-non-responder

source_name: Patient ID TKR18T


title: Expression data of rectal cancer TKR23T

description: training-non-responder

source_name: Patient ID TKR23T


title: Expression data of rectal cancer T47

description: training-non-responder

source_name: Patient ID T47


title: Expression data of rectal cancer TKR21T

description: training-non-responder

source_name: Patient ID TKR21T


title: Expression data of rectal cancer TKR29T

description: training-non-responder

source_name: Patient ID TKR29T


title: Expression data of rectal cancer TKR28T

description: training-non-responder

source_name: Patient ID TKR28T


title: Expression data of rectal cancer TKR09T

description: training-non-responder

source_name: Patient ID TKR09T


title: Expression data of rectal cancer T56

description: training-responder

source_name: Patient ID T56


title: Expression data of rectal cancer TKR27T

description: training-non-responder

source_name: Patient ID TKR27T


title: Expression data of rectal cancer T64

description: test-non-responder

source_name: Patient ID T64


title: Expression data of rectal cancer TKR02T

description: training-non-responder

source_name: Patient ID TKR02T


title: Expression data of rectal cancer T65

description: test-responder

source_name: Patient ID T65


title: Expression data of rectal cancer T59

description: test-responder

source_name: Patient ID T59


title: Expression data of rectal cancer T54

description: training-responder

source_name: Patient ID T54


title: Expression data of rectal cancer TKR17T

description: training-responder

source_name: Patient ID TKR17T


title: Expression data of rectal cancer T41

description: training-responder

source_name: Patient ID T41


title: Expression data of rectal cancer TKR35T

description: training-responder

source_name: Patient ID TKR35T


title: MV 6hr-3

status: Public on Jan 19 2006

first: Michael

last: Zilliox

address: 1510 Clifton Road

department: Microbiology and Immunology

institute: Emory University School of Medicine

description: CD14+ monocytes were grown for six days in IL-4 and GM-CSF.   The cells were then infected with measles virus and RNA was harvested 6 hours post-infection.

data_processing: Robust Multi-Array Analysis

source_name: MV-infected dendritic cells


title: Expression data of rectal cancer T38

description: training-responder

source_name: Patient ID T38


title: MV 24hr-3

description: CD14+ monocytes were grown for six days in IL-4 and GM-CSF.   The cells were then infected with measles virus and RNA was harvested 24 hours post-infection.


title: Control-3

description: CD14+ monocytes were grown for seven days in IL-4 and GM-CSF.

source_name: monocyte-derived dendritic cells


title: MV 12hr-2

description: CD14+ monocytes were grown for six days in IL-4 and GM-CSF.   The cells were then infected with measles virus and RNA was harvested 12 hours post-infection.


title: MV 6hr-2


title: MV 6hr-1


title: MV 24hr-2


title: Control-2


title: MV 3hr-2

description: CD14+ monocytes were grown for six days in IL-4 and GM-CSF.   The cells were then infected with measles virus and RNA was harvested 3 hours post-infection.


title: MV 12hr-1


title: LEP Sca1-ve - Liver Endothelial Progenitor Sca1-ve cells _sample 2

status: Public on Mar 28 2006

city: La Jolla

first: Sunil

last: Kurian

state: CA

address: 10550 N Torrey Pines Road

department: Molecular and Experimental Medicine

institute: The Scripps Research Institute

description: While others have reported that fetal liver contains a population of endothelial progenitors based on expression of cell surface markers or culture assays, this is the first proof of a CD31+Sca1+ progenitor by demonstrating highly efficient in vivo angiogenesis and a direct connection to the host vasculature. We have developed a novel isolation method based on collagenase digestion and culture on a fetal liver-derived feeder layer and demonstrate that the feeder cells or their supernatants are required for endothelial progenitor survival and proliferation. Proteogenomic profiling of the endothelial progenitors and the feeder cells was done with tandem mass spectrometry proteomics using MudPIT and gene transcript expression profiling using high density DNA microarrays. This approach identified a number of gene transcripts, proteins and candidate growth factor pathways that are likely to be involved in endothelial progenitor growth, differentiation and angiogenesis.

data_processing: Affymetrix GCOS data

label: SAPE

source_name: Fetal Liver

tag: Endothelial Cells


title: LEP Sca1+ve - Liver Endothelial Progenitor Sca1+ve cells_sample2

tag: Endothelial cells


title: Control-1


title: MV 24hr-1


title: MV 3hr-1

source_name: measles virus-infected dendritic cells


title: s5t4c

status: Public on Jan 17 2006

city: Bethesda

first: Anthony

middle: F.

last: Suffredini

state: MD

address: Building 10, Rm 7D43, 10 Center Drive

department: Critical Care Medicine Department

institute: National Institutes of Health

description: "Peripheral blood mononuclear cells were isolated 0, 30 min, 6 h, 24 h, and 7 day after saline challenge (control) using cell preparation tubes (Vacutainer® CPT). The PBMC layer was lysed with RLT buffer, homogenized, and then stored at –80°C. Total RNA was extracted as per RNeasy‚ Midi protocol (Qiagen). Double stranded cDNA was synthesized from total RNA (5 to 20 µg) using 7-d(T)24  primer and SuperScript‰ Double-Stranded cDNA Synthesis Kit and purified by phase lock gel-phenol/chloroform extraction followed by ethanol precipitation. Biotin-labeled cRNA was prepared by in vitro transcription using HighYield‰ RNA Transcript Labeling Kit followed by fragmentation with 5X fragmentation buffer.  Fragmented cRNA (10 µg) was hybridized to Affymetrix Hu95Av2 oligonucleotide probe arrays for 16 h at 45?C.  After removal of hybridization fluid, the arrays were washed, stained with streptavidin phycoerythrin (SAPE), and signal amplified by anti-streptavidin antibody using Affymetrix Fluidics Station 400.  Probe set signals were measured using Agilent GeneArray Scanner (Affymetrix‚, Santa Clara, CA)."

data_processing: Affymetrix Microarray Suite version 4.0

source_name: human peripheral blood mononuclear cells (healthy subject)

tag: "male subject, 18-45 yrs, peripheral blood mononuclear cells 168 h after intravenous saline challenge"


title: s5t1c

tag: "male subject, 18-45 yrs, peripheral blood mononuclear cells 30 minutes after intravenous saline challenge"


title: s5t2c

tag: "male subject, 18-45 yrs, peripheral blood mononuclear cells 6 h after intravenous saline challenge"


title: s4t2c


title: s2t1c

tag: "female subject, 18-45 yrs, peripheral blood mononuclear cells prior to 30 min intravenous saline challenge"


title: s5t0c

tag: "male subject, 18-45 yrs, peripheral blood mononuclear cells prior to (baseline - 0 h) intravenous saline challenge"


title: s2t4c

tag: "female subject, 18-45 yrs, peripheral blood mononuclear cells 168 h after intravenous saline challenge"


title: s4t3c

tag: "male subject, 18-45 yrs, peripheral blood mononuclear cells 24 h after intravenous saline challenge"


title: s4t4c


title: s4t1c


title: s2t3c

tag: "female subject, 18-45 yrs, peripheral blood mononuclear cells 24 h after intravenous saline challenge"


title: s4t0c


title: s3t3c


title: s3t2c

tag: "female subject, 18-45 yrs, peripheral blood mononuclear cells 6 h after intravenous saline challenge"


title: s2t2c


title: s3t0c

tag: "female subject, 18-45 yrs, peripheral blood mononuclear cells prior to (baseline - 0 h) intravenous saline challenge"


title: s3t1c


title: s2t0c


title: n11t7dPx

description: "Whole blood cell RNA was isolated at baseline, 3 h, 6 h, 24 h , and 7days after intravenous endotoxin challenge using PAXgene blood RNA tubes.  Total RNA was extracted and treated with DNase 1 as per PAXgene Blood RNA kit protocol with the following modifications: after 2 h incubation at room temperature, blood samples were kept for minimum 24 h at 4°C and total RNA precipitated overnight with 3M NaAc and 100% ethanol.  All samples were processed within 72 h from time of collection. Double stranded cDNA was synthesized from total RNA (5 to 20 µg) using 7-d(T)24  primer and SuperScriptä Double-Stranded cDNA Synthesis Kit and purified by phase lock gel-phenol/chloroform extraction followed by ethanol precipitation. Biotin-labeled cRNA was prepared by in vitro transcription using HighYieldä RNA Transcript Labeling Kit followed by fragmentation with 5X fragmentation buffer.  Fragmented cRNA (10 µg) was hybridized to Affymetrix Hu95Av2 oligonucleotide probe arrays for 16 h at 45°C.  After removal of hybridization fluid, the arrays were washed, stained with streptavidin phycoerythrin (SAPE), and signal amplified by anti-streptavidin antibody using Affymetrix Fluidics Station 400.  Probe set signals were measured using Agilent GeneArray Scanner (Affymetrixâ, Santa Clara, CA)."

source_name: human whole blood (healthy subject)

tag: "male subject, 18-45 yrs, whole blood cells 168 h after intravenous endotoxin challenge"


title: n11t6hPx

tag: "male subject, 18-45 yrs, whole blood cells 6 h after intravenous endotoxin challenge"


title: n11t24hPx

tag: "male subject, 18-45 yrs, whole blood cells 24 h after intravenous endotoxin challenge"


title: n10t7dPx


title: n11t0hPx

tag: "male subject, 18-45 yrs, whole blood cells prior to (baseline - 0 h) intravenous endotoxin challenge"


title: n10t6hPx


title: n9t24hPx

tag: "female subject, 18-45 yrs, whole blood cells 24 h after intravenous endotoxin challenge"


title: n9t6hPx

tag: "female subject, 18-45 yrs, whole blood cells 6 h after intravenous endotoxin challenge"


title: n9t7dPx

tag: "female subject, 18-45 yrs, whole blood cells 168 h after intravenous endotoxin challenge"


title: n11t3hPx

tag: "male subject, 18-45 yrs, whole blood cells 3 h after intravenous endotoxin challenge"


title: n10t24hPx


title: n10t3hPx


title: s5t3c


title: n11t6h

description: "Peripheral blood mononuclear cells were isolated 0, 30 min, 6 h, 24 h, and 7 day after intravenous endotoxin challenge using cell preparation tubes (Vacutainer® CPT). The PBMC layer was lysed with RLT buffer, homogenized, and then stored at –80°C. Total RNA was extracted as per RNeasy‚ Midi protocol (Qiagen). Double stranded cDNA was synthesized from total RNA (5 to 20 µg) using 7-d(T)24  primer and SuperScript‰ Double-Stranded cDNA Synthesis Kit and purified by phase lock gel-phenol/chloroform extraction followed by ethanol precipitation. Biotin-labeled cRNA was prepared by in vitro transcription using HighYield‰ RNA Transcript Labeling Kit followed by fragmentation with 5X fragmentation buffer.  Fragmented cRNA (10 µg) was hybridized to Affymetrix Hu95Av2 oligonucleotide probe arrays for 16 h at 45?C.  After removal of hybridization fluid, the arrays were washed, stained with streptavidin phycoerythrin (SAPE), and signal amplified by anti-streptavidin antibody using Affymetrix Fluidics Station 400.  Probe set signals were measured using Agilent GeneArray Scanner (Affymetrix‚, Santa Clara, CA)."

tag: "male subject, 18-45 yrs, peripheral blood mononuclear cells 6 h after intravenous endotoxin challenge"


title: n8t0hPx


title: n10t0hPx


title: n11t0h

tag: "male subject, 18-45 yrs, peripheral blood mononuclear cells prior to (baseline - 0 h) intravenous endotoxin challenge"


title: n8t24hPx


title: n8t7dPx


title: n8t6hPx

tag: "male subject, 18-45 yrs, whole blood cells  6 h after intravenous endotoxin challenge"


title: n9t3hPx

tag: "female subject, 18-45 yrs, whole blood cells 3 h after intravenous endotoxin challenge"


title: n10t6h


title: n11t24h

tag: "male subject, 18-45 yrs, peripheral blood mononuclear cells 24 h after intravenous endotoxin challenge"


title: n10t24h


title: n9t6h

tag: "female subject, 18-45 yrs, peripheral blood mononuclear cells 6 h after intravenous endotoxin challenge"


title: n9t30m

tag: "female subject, 18-45 yrs, peripheral blood mononuclear cells 30 min after intravenous endotoxin challenge"


title: n8t6h


title: n8t30m

tag: "male subject, 18-45 yrs, peripheral blood mononuclear cells 30 min after intravenous endotoxin challenge"


title: n10t0h


title: n8t7d

tag: "male subject, 18-45 yrs, peripheral blood mononuclear cells 168 h after intravenous endotoxin challenge"


title: n9t24h

tag: "female subject, 18-45 yrs, peripheral blood mononuclear cells 24 h after intravenous endotoxin challenge"


title: n9t0h

tag: "female subject, 18-45 yrs, peripheral blood mononuclear cells prior to (baseline - 0 h) intravenous endotoxin challenge"


title: n8t0h


title: n7t7d


title: n9t7d

tag: "female subject, 18-45 yrs, peripheral blood mononuclear cells 168 h after intravenous endotoxin challenge"


title: n6t24h


title: n6t7d


title: n7t24h


title: n7t0h


title: n6t30m


title: n6t6h


title: n7t6h


title: n7t30m


title: n5t0h


title: n5t6h


title: n5t24h


title: n5t30m


title: n4t30m


title: n6t0h


title: n4t6h


title: n5t7d


title: 1749 (HG-U95A)

status: Public on Jan 04 2006

city: Philadelphia

first: Jayanti

last: Jagannathan

state: PA

address: 34th & Civic center blvd

department: Oncology

institute: Childrens Hospital of Philadelphia

description: Primary neuroblastoma tumor.  Tumor annotation : ND is Not Done.

data_processing: Statistical modeling of probe set behavior was conducted using Probe Profiler (Corimbia, Berkeley, CA) as described by the manufacturer. The software implements a model-based approach for data extraction from probe sets and weights probe pairs based on consistency of performance. Normalization to remove chip-to-chip variation is accomplished by subtracting the second percentile intensity value and dividing by the interquartile range (IQR). A quantitative expression score (e-score) is then calculated for each probe set.

label: Biotin

source_name: Primary Tumor

label_protocol: Standard Affymetrix protocol

tag: Age Diagnosis

value: 841, INSS Stage:4, MYCN:Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:ND


title: n4t7d


title: 1994 (HG-U95A)

value: 1422, INSS Stage:4, MYCN:Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:ND


title: 1243 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 577, INSS Stage:4, MYCN:Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:97


title: n4t24h


title: 1287 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 746, INSS Stage:4, MYCN:Amplified, 1p36 LOH:LOH, 11q23 LOH:LOH, Unb11qLOH:Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:100


title: 1246 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1564, INSS Stage:4, MYCN:Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:100


title: 1257 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 3972, INSS Stage:4, MYCN:Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:100


title: 1129 (HG-U95A)

description: Primary neuroblastoma tumor. Tumor annotation : ND is Not Done.

value: 823, INSS Stage:4, MYCN:Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:ND


title: n4t0h


title: 1266 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 699, INSS Stage:4, MYCN:Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:100


title: 1288 (HG-U95A)

value: 1626, INSS Stage:4, MYCN:Amplified, 1p36 LOH:LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:ND, Tumor %:97


title: 1066 (HG-U95A)

value: 200, INSS Stage:4, MYCN:Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:ND, Tumor %:93


title: 1068 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 405, INSS Stage:4, MYCN:Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:85


title: 1109 (HG-U95A)

value: 1502, INSS Stage:4, MYCN:Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:ND, Tumor %:88


title: 493 (HG-U95A)

value: 1500, INSS Stage:4, MYCN:Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:ND, Tumor %:100


title: 1009 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1240, INSS Stage:4, MYCN:Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:98


title: 1043 (HG-U95A)

value: 1119, INSS Stage:4, MYCN:Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:ND, Tumor %:93


title: 969 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 364, INSS Stage:4, MYCN:Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:97


title: 1034 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 709, INSS Stage:4, MYCN:Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:99


title: 433 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1083, INSS Stage:4, MYCN:Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:100


title: 241 (HG-U95A)

value: 177, INSS Stage:4, MYCN:Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:ND, Tumor %:95


title: 2184 (HG-U95A)

value: 1851, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:ND, 11q23 LOH:ND, Unb11qLOH:ND, 17q gain:ND, Tumor %:ND


title: 260 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 235, INSS Stage:4, MYCN:Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:96


title: 2108 (HG-U95A)

value: 1344, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:ND


title: 1995 (HG-U95A)

value: 709, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:ND


title: 1554 (HG-U95A)

label_protocol: Standard Affymetrix protocol.

value: 1525, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:LOH, 11q23 LOH:LOH, Unb11qLOH:Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:ND


title: 1310 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 2069, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:100


title: 1326 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 946, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:90


title: 1258 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 632, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:100


title: 1236 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1390, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:ND, Unb11qLOH:ND, 17q gain:Unbalanced Gain, Tumor %:100


title: 1220 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1810, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:LOH, 11q23 LOH:LOH, Unb11qLOH:Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:94


title: 1194 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1367, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:93


title: 1204 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1105, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:LOH, 11q23 LOH:LOH, Unb11qLOH:Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:97


title: 1167 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1157, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:94


title: 1012 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1843, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:100


title: 1092 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1634, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:94


title: 982 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1544, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:100


title: 1097 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 512, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:87


title: 1174 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1739, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:83


title: 1156 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1004, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:89


title: 1100 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1279, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:92


title: 1218 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1133, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:96


title: 1118 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 4697, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:90


title: 499 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1873, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:96


title: 1213 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1214, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:91


title: 974 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1232, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:100


title: 396 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 417, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:99


title: 205 (HG-U95A)

value: 2321, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:ND, Tumor %:90


title: 338 (HG-U95A)

value: 730, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:ND


title: 73 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 4580, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:85


title: 427 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 4249, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:96


title: 1303 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 519, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:92


title: 158 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 4174, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:96


title: 1290 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 238, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:98


title: 1196 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 145, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:97


title: 1292 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 433, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:100


title: 1250 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 859, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:96


title: 495 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 804, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:99


title: 58 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 723, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:LOH, 11q23 LOH:LOH, Unb11qLOH:Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:72


title: 1267 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 470, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:96


title: 1317 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 348, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:98


title: 1133 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 510, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:90


title: 415 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 182, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:99


title: 1052 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 126, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:93


title: 2634 (HG-U95A)

value: 415, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:ND


title: 417 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 215, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:98


title: 1039 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 269, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:100


title: 1556 (HG-U95A)

value: 26, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:ND


title: 1069 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 188, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:91


title: 2150 (HG-U95A)

value: 219, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:ND


title: 11 (HG-U95A)

value: 336, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:ND, Tumor %:93


title: 15 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 348, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:88


title: 430 (HG-U95A)

value: 160, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:Unbalanced LOH, 17q gain:ND, Tumor %:98


title: 975 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 1786, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:100


title: 2175 (HG-U95A)

value: 270, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:ND


title: 46 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 193, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:87


title: 1322 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 188, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:88


title: 1324 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 12, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:90


title: 1285 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 42, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:100


title: 1256 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 105, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:100


title: 1254 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 303, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:100


title: 1319 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 231, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:73


title: 1033 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 66, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:97


title: 2204 (HG-U95A)

value: 358, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:ND


title: 1260 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 405, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:100


title: 1142 (HG-U95A)

value: 52, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:ND


title: 1059 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 91, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:97


title: 1253 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 9, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:90


title: 1073 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 117, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:93


title: 1122 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 478, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:100


title: 1291 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 325, INSS Stage:3, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:97


title: 1013 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 488, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:100


title: 1030 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 19, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:95


title: 1139 (HG-U95A)

value: 388, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:ND, Tumor %:88


title: 1170 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 307, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:96


title: 1005 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 229, INSS Stage:1*, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:100


title: 1251 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 17, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:100


title: 406 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 141, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:100


title: 491 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 69, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:90


title: 989 (HG-U95A)

value: 70, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:ND, Tumor %:100


title: 401 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 392, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:90


title: Fetal Brain (HG-U95A)

description: Control

source_name: Fetal Brain

tag: Control


title: 37 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 38, INSS Stage:1, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:No LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:No Unbalanced Gain, Tumor %:78


title: Universal Human Reference RNA Affy4h_labeling replicate 5

status: Public on Jan 01 2006

description: Stratagene’s Universal Human Reference RNA is composed of total RNA from 10 human cell lines. The reference RNA is designed to be used as a reference for microarray gene-profiling experiments. Since RNA species differ in abundance between cell lines, an ideal reference sample should represent these different RNAs. Equal quantities of DNase-treated total RNA from each cell line were pooled to make the Universal Human Reference RNA. The ten cell lines are cell lines of the adenocarcinoma of the mammary gland, melanoma, liver hepatoblastoma, liposarcoma, adenocarcinoma of the cervix, histocytic lymphoma (macrophage, histocyte), embryonal carcinoma of the testis, lymphoblastic leukemia (T lymphoblast), glioblastoma of brain, and plasmacytoma (myeloma; B lymphocyte).

data_processing: Affymetrix Microarray Suite version 5.0 for detection calls and detection p-value; dChip v1.3 algorithm is used to calculate the signal intensity values with the invariant set normalization and the PM-only model.

source_name: Universal Human Reference RNA, Affy4h_labeling

label_protocol: The Affymetrix GeneChip® Expression 3’-amplification Reagents for IVT labeling kit is used. However, the length of the in vitro transcription reaction is truncated to 4 hours. Therefore, it is called the 'Affy4h' method in the paper. Approximately 1 µg of total RNA was processed to produce biotinylated cRNA targets. UTP-biotin was used for labeling and the in vitro transcription reaction lasts for 4 hours.

tag: Human Cell Lines, malignancy


title: Universal Human Reference RNA Affy4h_labeling replicate 1


title: Universal Human Reference RNA Enzo_labeling replicate 5

source_name: Universal Human Reference RNA, Enzo_labeling

label_protocol: The Enzo BioArray High Yield™ RNA Transcript Labeling Kit is used. It is called the 'Enzo' method in the paper. Approximately 5 µg of total RNA was processed to produce biotinylated cRNA targets. UTP-biotin and CTP-biotin were used for labeling and the in vitro transcription reaction lasts for 4 hours.


title: Universal Human Reference RNA Enzo_labeling replicate 4


title: Universal Human Reference RNA Affy4h_labeling replicate 3


title: Universal Human Reference RNA Affy4h_labeling replicate 4


title: Universal Human Reference RNA Enzo_labeling replicate 2


title: Universal Human Reference RNA CodeLink_labeling replicate 1

source_name: Universal Human Reference RNA, CodeLink_labeling

label_protocol: The CodeLink Expression Assay Reagent Kit (GE Healthcare, Piscataway, NJ) is used. It is called the 'CodeLink' method in the paper. Approximately 1 µg of total RNA was processed to produce biotinylated cRNA targets. UTP-biotin was used for labeling and the in vitro transcription reaction lasts for 14 hours.


title: Universal Human Reference RNA Enzo_labeling replicate 3


title: Universal Human Reference RNA Enzo_labeling replicate 1


title: Universal Human Reference RNA CodeLink_labeling replicate 5


title: Universal Human Reference RNA CodeLink_labeling replicate 2


title: Universal Human Reference RNA Affy_labeling replicate 3

source_name: Universal Human Reference RNA, Affy_labeling

label_protocol: Affymetrix GeneChip® Expression 3’-amplification Reagents for IVT labeling kit is used. It is called the 'Affy' method in the paper. Approximately 1 µg of total RNA was processed to produce biotinylated cRNA targets. UTP-biotin was used for labeling and the in vitro transcription reaction lasts for 16 hours.


title: Universal Human Reference RNA CodeLink_labeling replicate 3


title: Universal Human Reference RNA Affy_labeling replicate 5


title: Universal Human Reference RNA Affy4h_labeling replicate 2


title: 1163 (HG-U95A)

description: Primary neuroblastoma tumor.

value: 362, INSS Stage:4, MYCN:Not Amplified, 1p36 LOH:No LOH, 11q23 LOH:LOH, Unb11qLOH:No Unbalanced LOH, 17q gain:Unbalanced Gain, Tumor %:86


title: Universal Human Reference RNA CodeLink_labeling replicate 4


title: Universal Human Reference RNA Affy_labeling replicate 2


title: Universal Human Reference RNA Affy_labeling replicate 1

label_protocol: The Affymetrix GeneChip® Expression 3’-amplification Reagents for IVT labeling kit is used. It is called the 'Affy' method in the paper. Approximately 1 µg of total RNA was processed to produce biotinylated cRNA targets. UTP-biotin was used for labeling and the in vitro transcription reaction lasts for 16 hours.


title: Hs36 9N2

status: Public on Dec 20 2005

city: Denver

first: Robert

middle: S

last: Stearman

state: CO

address: 4200 E Ninth Ave

department: Medicine/Pulmonary

institute: UCHSC

description: adjacent normal lung

source_name: lung tissue


title: Hs38 10N1

description: adjacent normal lung


title: Hs32 8N2

description: adjacent normal lung


title: Hs34 9N1

description: adjacent normal lung


title: Hs16 4N2

description: adjacent normal lung


title: Hs18 5N1

description: adjacent normal lung


title: Hs13 4N1

description: adjacent normal lung


title: Hs12 3N2

description: adjacent normal lung


title: Hs30 8N1

description: adjacent normal lung


title: Hs40 10N2

description: adjacent normal lung


title: Hs24 6N2

description: adjacent normal lung


title: Hs10 3N1

description: adjacent normal lung


title: Hs22 6N1

description: adjacent normal lung


title: Hs20 5N2

description: adjacent normal lung


title: Hs26 7N1

description: adjacent normal lung


title: Hs08 2N2

description: adjacent normal lung


title: Hs06 2N1

description: adjacent normal lung


title: Hs04 1N2

description: adjacent normal lung


title: Hs02 1N1

description: adjacent normal lung


title: Hs23 6T2

description: tumor lung


title: Universal Human Reference RNA Affy_labeling replicate 4


title: Hs31 8T2

description: tumor lung


title: Hs37 10T1

description: tumor lung


title: Hs33 9T1

description: tumor lung


title: Hs27 7T2

description: tumor lung


title: Hs19 5T2

description: tumor lung


title: Hs14 4T1

description: tumor lung


title: Hs17 5T1

description: tumor lung


title: Hs39 10T2

description: tumor lung


title: Hs35 9T2

description: tumor lung


title: Hs11 3T2

description: tumor lung


title: Hs29 8T1

description: tumor lung


title: Hs15 4T2

description: tumor lung


title: Hs28 7T1

description: tumor lung


title: Hs21 6T1

description: tumor lung


title: Hs05 2T1

description: tumor lung


title: Hs09 3T1

description: tumor lung


title: Human LNCaP Cells Following Treatment with DHEA-Experiment #111502

status: Public on Nov 18 2005

city: Rockville

first: Vernon

middle: Eugene

last: Steele

address: 6130 Executive Blvd

department: DIvision of Cancer Prevention

institute: National Cancer Institute

description: This data set labeled "dchip 111502DHEA" were from cells treated with dehydroepiandosterone (DHEA) in Experiment #111502.

hyb_protocol: Affymetrix Eukaryote instructions were followed

data_processing: dchip

source_name: Human LNCaP Prostate cancer cells

growth_protocol: Cells were grown in M199:F12 (1:1) medium with penicillin, streptomycin, L-glutamine and 5% Fetal Bovine Serum at 37 degrees C

extract_protocol: Total RNA was extracted using Trizol according to Mfg's instructions. The RNA was precipitated by slow addition of 70% Ethanol at room temperataure. The percipitate was loaded onto RNAeasy columns following mfg's instructions. Samples were stored at -80 C.

treatment_protocol: Cells were treated for 48 hours with the hormones or solvent, then harvested in asynchronous culture.

tag: LNCaP cells in culture


title: on Human LNCaP Cells Following Treatment with Ethanol in Experiment #011403

description: This data set labeled "dchip 011403EtOH"were from cells treated with ethanol in Experiment #011403.

scan_protocol: Affymetrix Eukaryote instructions were followed

tag: LNCaP cells in culture treated with Ethanol


title: Human LNCaP Cells Following Treatment with dihydrotestosterone in experiment #022803

description: This data set labeled "dchip 022803DHT"were from cells treated with dihydrotestosterone in Experiment #022803.

label_protocol: Affymetrix Eukaryote instructions were followed

tag: LNCaP cells in culture treated with dihydrotestosterone


title: Differential Gene Expression on Human LNCaP Cells Following Treatment with DHEA versus DHT

description: This data set labeled "dchip 111502dhT" were from cells treated with dihydrotestosterone in Experiment #111502.


title: Hs03 1T2

description: tumor lung


title: Human LNCaP Cells Following Treatment with DHEA-Experiment #022803

description: This data set labeled "dchip 022803DHEA" " were from cells treated with DHEA in Experiment #022803

tag: LNCaP cells in culture treated with DHEA


title: Human LNCaP Cells Following Treatment with DHEA

description: This data set labeled "dchip 011403DHEA" were from cells treated with dehydroepiandrosterone (DHEA) in Experiment #011403.


title: Hs01 1T1

description: tumor lung


title: Human LNCaP Cells Following Treatment with Ethanol in Experiment #022803

description: This data set labeled "dchip 022803EtOH"were from cells treated with ethanol in Experiment #022803.

tag: LNCaP cells in culture treated with Ethanol in experiment #022803.


title: T96-127

status: Public on Nov 07 2005

city: Durham

first: Joseph

middle: R.

last: Nevins

state: NC

address: 2133 CIEMAS, 101 Science Dr.

department: IGSP

institute: Duke University

description: frozen tissue of primary breast tumors

source_name: frozen tissue of primary breast tumors

value: Surv(months):66.563; STATUS (0=alive, 1=dead):0


title: Human LNCaP Cells Following Treatment with dihydrotestosterone

description: This data set labeled "dchip 011403DHT" were from cells treated with dihydrotestosterone in Experiment #011403.

tag: LNCaP cells in culture treated with DHT


title: T96-136

description: frozen tissue of primary breast tumors

value: Surv(months):98.398; STATUS (0=alive, 1=dead):0


title: Human LNCaP Cells Following Treatment with DMSO-Experiment #111502

description: This data set labeled "dchip 111502DMSOr" were from cells treated with dimethylsulfoxide (DMSO), the control solvent, in Experiment #111502.


title: T93-2

description: frozen tissue of primary breast tumors

value: Surv(months):130.004; STATUS (0=alive, 1=dead):0


title: IMR90-nonDividing 2

status: Public on Nov 10 2005

city: philadelphia

first: Chris

last: Hoffmann

address: 3610 hamilton walk

institute: University of Pennsylvania

description: IMR-90 cells (initially passaged 36 times) were cultured in DMEM with 10% FBS until the cells reached 100% confluence, at which point the medium was substituted to contain only 0.5% FBS. The cells were cultivated for 2 weeks prior to harvesting for RNA extraction.

data_processing: Signal value data was generated using Affymetrix Microarray Suit 5.1.

label: Labeling was performed as recommended by Affymetrix for the HU95Av2 arrays.

source_name: IMR90 cells, primary lung fibroblasts.

tag: IMR-90 growth arrested cells (by serum starvation and contact inhibition).


title: IMR90-nonDividing 1


title: T96-85

description: frozen tissue of primary breast tumors

value: Surv(months):103.162; STATUS (0=alive, 1=dead):0


title: T96-94

description: frozen tissue of primary breast tumors

value: Surv(months):60.879; STATUS (0=alive, 1=dead):0


title: Hs07 2T2

description: tumor lung


title: T95-194

description: frozen tissue of primary breast tumors

value: Surv(months):112.033; STATUS (0=alive, 1=dead):0


title: T95-74

description: frozen tissue of primary breast tumors

value: Surv(months):108.747; STATUS (0=alive, 1=dead):0


title: T95-168

description: frozen tissue of primary breast tumors

value: Surv(months):36.567; STATUS (0=alive, 1=dead):0


title: T95-40

description: frozen tissue of primary breast tumors

value: Surv(months):109.372; STATUS (0=alive, 1=dead):0


title: T94-72

description: frozen tissue of primary breast tumors

value: Surv(months):89.495; STATUS (0=alive, 1=dead):1


title: T95-31

description: frozen tissue of primary breast tumors

value: Surv(months):115.844; STATUS (0=alive, 1=dead):0


title: T94-71

description: frozen tissue of primary breast tumors

value: Surv(months):120.936; STATUS (0=alive, 1=dead):0


title: T97-94

description: frozen tissue of primary breast tumors

value: Surv(months):94.719; STATUS (0=alive, 1=dead):0


title: T97-191

description: frozen tissue of primary breast tumors

value: Surv(months):89.035; STATUS (0=alive, 1=dead):0


title: T94-74

description: frozen tissue of primary breast tumors

value: Surv(months):38.965; STATUS (0=alive, 1=dead):0


title: T92-37

description: frozen tissue of primary breast tumors

value: Surv(months):149.684; STATUS (0=alive, 1=dead):0


title: T95-28

description: frozen tissue of primary breast tumors

value: Surv(months):105.725; STATUS (0=alive, 1=dead):0


title: T97-90

description: frozen tissue of primary breast tumors

value: Surv(months):95.869; STATUS (0=alive, 1=dead):0


title: T97-75

description: frozen tissue of primary breast tumors

value: Surv(months):88.049; STATUS (0=alive, 1=dead):0


title: T92-58

description: frozen tissue of primary breast tumors

value: Surv(months):94.094; STATUS (0=alive, 1=dead):0


title: T97-281

description: frozen tissue of primary breast tumors

value: Surv(months):79.146; STATUS (0=alive, 1=dead):0


title: T97-80

description: frozen tissue of primary breast tumors

value: Surv(months):84.14; STATUS (0=alive, 1=dead):0


title: T95-162

description: frozen tissue of primary breast tumors

value: Surv(months):47.934; STATUS (0=alive, 1=dead):1


title: T97-71

description: frozen tissue of primary breast tumors

value: Surv(months):52.041; STATUS (0=alive, 1=dead):0


title: T97-51

description: frozen tissue of primary breast tumors

value: Surv(months):96.427; STATUS (0=alive, 1=dead):0


title: T97-43

description: frozen tissue of primary breast tumors

value: Surv(months):96.559; STATUS (0=alive, 1=dead):0


title: T97-19

description: frozen tissue of primary breast tumors

value: Surv(months):80.361; STATUS (0=alive, 1=dead):0


title: KF-94

description: frozen tissue of primary breast tumors

value: Surv(months):72.871; STATUS (0=alive, 1=dead):0


title: T97-17

description: frozen tissue of primary breast tumors

value: Surv(months):88.674; STATUS (0=alive, 1=dead):0


title: T96-167

description: frozen tissue of primary breast tumors

value: Surv(months):96.066; STATUS (0=alive, 1=dead):0


title: T96-159

description: frozen tissue of primary breast tumors

value: Surv(months):104.838; STATUS (0=alive, 1=dead):0


title: KF-105

description: frozen tissue of primary breast tumors

value: Surv(months):61.602; STATUS (0=alive, 1=dead):0


title: KF-106

description: frozen tissue of primary breast tumors

value: Surv(months):68.172; STATUS (0=alive, 1=dead):0


title: KF-104

description: frozen tissue of primary breast tumors

value: Surv(months):60.517; STATUS (0=alive, 1=dead):0


title: KF-200

description: frozen tissue of primary breast tumors

value: Surv(months):94.883; STATUS (0=alive, 1=dead):0


title: KF-207

description: frozen tissue of primary breast tumors

value: Surv(months):99.384; STATUS (0=alive, 1=dead):1


title: KF-193

description: frozen tissue of primary breast tumors

value: Surv(months):140.616; STATUS (0=alive, 1=dead):0


title: KF-196

description: frozen tissue of primary breast tumors

value: Surv(months):31.244; STATUS (0=alive, 1=dead):1


title: KF-95

description: frozen tissue of primary breast tumors

value: Surv(months):60.55; STATUS (0=alive, 1=dead):0


title: KF-189

description: frozen tissue of primary breast tumors

value: Surv(months):29.667; STATUS (0=alive, 1=dead):1


title: KF-194

description: frozen tissue of primary breast tumors

value: Surv(months):27.598; STATUS (0=alive, 1=dead):1


title: KF-187

description: frozen tissue of primary breast tumors

value: Surv(months):21.815; STATUS (0=alive, 1=dead):1


title: T96-250

description: frozen tissue of primary breast tumors

value: Surv(months):96.69; STATUS (0=alive, 1=dead):0


title: KF-204

description: frozen tissue of primary breast tumors

value: Surv(months):57.528; STATUS (0=alive, 1=dead):1


title: T96-195

description: frozen tissue of primary breast tumors

value: Surv(months):100.961; STATUS (0=alive, 1=dead):0


title: KF-183

description: frozen tissue of primary breast tumors

value: Surv(months):24.805; STATUS (0=alive, 1=dead):1


title: KF-182

description: frozen tissue of primary breast tumors

value: Surv(months):156.156; STATUS (0=alive, 1=dead):0


title: KF-203

description: frozen tissue of primary breast tumors

value: Surv(months):108.025; STATUS (0=alive, 1=dead):1


title: KF-188

description: frozen tissue of primary breast tumors

value: Surv(months):24.542; STATUS (0=alive, 1=dead):1


title: KF-195

description: frozen tissue of primary breast tumors

value: Surv(months):56.903; STATUS (0=alive, 1=dead):1


title: KF-113

description: frozen tissue of primary breast tumors

value: Surv(months):62.127; STATUS (0=alive, 1=dead):0


title: KF-176

description: frozen tissue of primary breast tumors

value: Surv(months):19.811; STATUS (0=alive, 1=dead):1


title: KF-201

description: frozen tissue of primary breast tumors

value: Surv(months):56.148; STATUS (0=alive, 1=dead):1


title: KF-117

description: frozen tissue of primary breast tumors

value: Surv(months):37.421; STATUS (0=alive, 1=dead):0


title: KF-184

description: frozen tissue of primary breast tumors

value: Surv(months):141.634; STATUS (0=alive, 1=dead):1


title: KF-97

description: frozen tissue of primary breast tumors

value: Surv(months):31.671; STATUS (0=alive, 1=dead):1


title: KF-69

description: frozen tissue of primary breast tumors

value: Surv(months):86.374; STATUS (0=alive, 1=dead):0


title: KF-155

description: frozen tissue of primary breast tumors

value: Surv(months):28.485; STATUS (0=alive, 1=dead):1


title: KF-159

description: frozen tissue of primary breast tumors

value: Surv(months):46.16; STATUS (0=alive, 1=dead):1


title: KF-151

description: frozen tissue of primary breast tumors

value: Surv(months):36.008; STATUS (0=alive, 1=dead):1


title: KF-120

description: frozen tissue of primary breast tumors

value: Surv(months):66.727; STATUS (0=alive, 1=dead):0


title: KF-98

description: frozen tissue of primary breast tumors

value: Surv(months):53.421; STATUS (0=alive, 1=dead):0


title: KF-145

description: frozen tissue of primary breast tumors

value: Surv(months):26.612; STATUS (0=alive, 1=dead):1


title: KF-126

description: frozen tissue of primary breast tumors

value: Surv(months):16.197; STATUS (0=alive, 1=dead):1


title: KF-137

description: frozen tissue of primary breast tumors

value: Surv(months):11.992; STATUS (0=alive, 1=dead):1


title: KF-130

description: frozen tissue of primary breast tumors

value: Surv(months):29.569; STATUS (0=alive, 1=dead):1


title: KF-178

description: frozen tissue of primary breast tumors

value: Surv(months):7.326; STATUS (0=alive, 1=dead):1


title: KF-129

description: frozen tissue of primary breast tumors

value: Surv(months):82.168; STATUS (0=alive, 1=dead):1


title: KF-134

description: frozen tissue of primary breast tumors

value: Surv(months):54.702; STATUS (0=alive, 1=dead):1


title: KF-143

description: frozen tissue of primary breast tumors

value: Surv(months):45.273; STATUS (0=alive, 1=dead):1


title: KF-90

description: frozen tissue of primary breast tumors

value: Surv(months):69.947; STATUS (0=alive, 1=dead):0


title: KF-153

description: frozen tissue of primary breast tumors

value: Surv(months):41.002; STATUS (0=alive, 1=dead):1


title: KF-140

description: frozen tissue of primary breast tumors

value: Surv(months):99.581; STATUS (0=alive, 1=dead):1


title: KF-154

description: frozen tissue of primary breast tumors

value: Surv(months):97.61; STATUS (0=alive, 1=dead):0


title: KF-139

description: frozen tissue of primary breast tumors

value: Surv(months):60.715; STATUS (0=alive, 1=dead):0


title: KF-138

description: frozen tissue of primary breast tumors

value: Surv(months):74.612; STATUS (0=alive, 1=dead):1


title: KF-70

description: frozen tissue of primary breast tumors

value: Surv(months):83.91; STATUS (0=alive, 1=dead):0


title: KF-135

description: frozen tissue of primary breast tumors

value: Surv(months):34.267; STATUS (0=alive, 1=dead):1


title: KF-142

description: frozen tissue of primary breast tumors

value: Surv(months):9.199; STATUS (0=alive, 1=dead):1


title: KF-133

description: frozen tissue of primary breast tumors

value: Surv(months):49.248; STATUS (0=alive, 1=dead):0


title: KF-149

description: frozen tissue of primary breast tumors

value: Surv(months):25.462; STATUS (0=alive, 1=dead):1


title: KF-131

description: frozen tissue of primary breast tumors

value: Surv(months):55.359; STATUS (0=alive, 1=dead):1


title: KF-160

description: frozen tissue of primary breast tumors

value: Surv(months):79.343; STATUS (0=alive, 1=dead):0


title: KF-125

description: frozen tissue of primary breast tumors

value: Surv(months):59.63; STATUS (0=alive, 1=dead):1


title: KF-128

description: frozen tissue of primary breast tumors

value: Surv(months):99.121; STATUS (0=alive, 1=dead):0


title: KF-127

description: frozen tissue of primary breast tumors

value: Surv(months):68.271; STATUS (0=alive, 1=dead):1


title: KF-132

description: frozen tissue of primary breast tumors

value: Surv(months):17.938; STATUS (0=alive, 1=dead):1


title: KF-152

description: frozen tissue of primary breast tumors

value: Surv(months):27.663; STATUS (0=alive, 1=dead):1


title: KF-124

description: frozen tissue of primary breast tumors

value: Surv(months):35.581; STATUS (0=alive, 1=dead):1


title: KF-147

description: frozen tissue of primary breast tumors

value: Surv(months):103.688; STATUS (0=alive, 1=dead):0


title: KF-146

description: frozen tissue of primary breast tumors

value: Surv(months):17.577; STATUS (0=alive, 1=dead):1


title: KF-157

description: frozen tissue of primary breast tumors

value: Surv(months):40.706; STATUS (0=alive, 1=dead):1


title: KF-141

description: frozen tissue of primary breast tumors

value: Surv(months):40.312; STATUS (0=alive, 1=dead):0


title: KF-123

description: frozen tissue of primary breast tumors

value: Surv(months):15.671; STATUS (0=alive, 1=dead):1


title: KF-150

description: frozen tissue of primary breast tumors

value: Surv(months):69.782; STATUS (0=alive, 1=dead):0


title: KF-136

description: frozen tissue of primary breast tumors

value: Surv(months):22.012; STATUS (0=alive, 1=dead):1


title: KF-110

description: frozen tissue of primary breast tumors

value: Surv(months):53.914; STATUS (0=alive, 1=dead):0


title: KF-144

description: frozen tissue of primary breast tumors

value: Surv(months):105.133; STATUS (0=alive, 1=dead):0


title: KF-79

description: frozen tissue of primary breast tumors

value: Surv(months):52.6; STATUS (0=alive, 1=dead):0


title: KF-77

description: frozen tissue of primary breast tumors

value: Surv(months):69.881; STATUS (0=alive, 1=dead):0


title: KF-76

description: frozen tissue of primary breast tumors

value: Surv(months):60.78; STATUS (0=alive, 1=dead):0


title: KF-67

description: frozen tissue of primary breast tumors

value: Surv(months):42.185; STATUS (0=alive, 1=dead):1


title: T00-214

description: frozen tissue of primary breast tumors

value: Surv(months):13.7; STATUS (0=alive, 1=dead):1


title: T00-109

description: frozen tissue of primary breast tumors

value: Surv(months):61.142; STATUS (0=alive, 1=dead):0


title: T00-50

description: frozen tissue of primary breast tumors

value: Surv(months):59.992; STATUS (0=alive, 1=dead):0


title: T01-585

description: frozen tissue of primary breast tumors

value: Surv(months):5.651; STATUS (0=alive, 1=dead):0


title: T00-64

description: frozen tissue of primary breast tumors

value: Surv(months):62.292; STATUS (0=alive, 1=dead):0


title: T01-495

description: frozen tissue of primary breast tumors

value: Surv(months):42.119; STATUS (0=alive, 1=dead):1


title: T01-534

description: frozen tissue of primary breast tumors

value: Surv(months):39.326; STATUS (0=alive, 1=dead):0


title: T01-255

description: frozen tissue of primary breast tumors

value: Surv(months):18.595; STATUS (0=alive, 1=dead):0


title: T01-310

description: frozen tissue of primary breast tumors

value: Surv(months):45.963; STATUS (0=alive, 1=dead):0


title: T01-838

description: frozen tissue of primary breast tumors

value: Surv(months):7.819; STATUS (0=alive, 1=dead):0


title: T01-772

description: frozen tissue of primary breast tumors

value: Surv(months):26.185; STATUS (0=alive, 1=dead):1


title: T01-748

description: frozen tissue of primary breast tumors

value: Surv(months):41.561; STATUS (0=alive, 1=dead):0


title: T01-52

description: frozen tissue of primary breast tumors

value: Surv(months):30.094; STATUS (0=alive, 1=dead):0


title: T00-622

description: frozen tissue of primary breast tumors

value: Surv(months):52.304; STATUS (0=alive, 1=dead):0


title: T00-70

description: frozen tissue of primary breast tumors

value: Surv(months):62.062; STATUS (0=alive, 1=dead):0


title: T01-659

description: frozen tissue of primary breast tumors

value: Surv(months):41.429; STATUS (0=alive, 1=dead):0


title: T01-591

description: frozen tissue of primary breast tumors

value: Surv(months):43.565; STATUS (0=alive, 1=dead):0


title: T01-605

description: frozen tissue of primary breast tumors

value: Surv(months):23.918; STATUS (0=alive, 1=dead):1


title: T01-569

description: frozen tissue of primary breast tumors

value: Surv(months):42.645; STATUS (0=alive, 1=dead):0


title: T01-618

description: frozen tissue of primary breast tumors

value: Surv(months):42.743; STATUS (0=alive, 1=dead):0


title: T01-344

description: frozen tissue of primary breast tumors

value: Surv(months):16.854; STATUS (0=alive, 1=dead):0


title: T01-522

description: frozen tissue of primary breast tumors

value: Surv(months):40.444; STATUS (0=alive, 1=dead):0


title: T01-514

description: frozen tissue of primary breast tumors

value: Surv(months):44.189; STATUS (0=alive, 1=dead):0


title: T01-496

description: frozen tissue of primary breast tumors

value: Surv(months):27.039; STATUS (0=alive, 1=dead):0


title: T01-463

description: frozen tissue of primary breast tumors

value: Surv(months):43.893; STATUS (0=alive, 1=dead):0


title: T01-503

description: frozen tissue of primary breast tumors

value: Surv(months):43.236; STATUS (0=alive, 1=dead):0


title: T01-472

description: frozen tissue of primary breast tumors

value: Surv(months):43.959; STATUS (0=alive, 1=dead):0


title: T01-502

description: frozen tissue of primary breast tumors

value: Surv(months):42.678; STATUS (0=alive, 1=dead):0


title: T01-410

description: frozen tissue of primary breast tumors

value: Surv(months):42.908; STATUS (0=alive, 1=dead):0


title: T01-466

description: frozen tissue of primary breast tumors

value: Surv(months):44.517; STATUS (0=alive, 1=dead):0